National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide Patients were eligible for the ...

A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis No ...

image: As we know, a malignant tumor is a complex system of mutated cells which constantly interacts with and involves healthy cells in the body. This specificity of malignant neoplasms greatly ...

CCR8 is highly expressed on immunosuppressive regulatory T cells (Tregs) in various solid tumors, making it a potential target to enhance antitumor immunity and the efficacy of cancer therapies, ...

Table 3. Calculated Pearson and Spearman's rgcorrelation coefficients between each molecular descriptor and log Keq. The predictive equations are presented for the three sets of drugs analyzed (All ...

Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days LONDON and PHILADELPHIA - December ...

Plants have been used as the source of drugs for long ages, and as of today, approximately 70,000 species have been screened for their potential utility as medicines. In recent decades, several ...